II
118THCONGRESS
1
STSESSION S. 2922
To advance population research for chronic pain.
IN THE SENATE OF THE UNITED STATES
SEPTEMBER26 (legislative day, SEPTEMBER22), 2023
Mr. C
ASEY(for himself, Mrs. BLACKBURN, Mr. KAINE, and Mr. CRAMER) in-
troduced the following bill; which was read twice and referred to the Com-
mittee on Health, Education, Labor, and Pensions
A BILL
To advance population research for chronic pain.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled, 2
SECTION 1. SHORT TITLE. 3
This Act may be cited as the ‘‘Advancing Research 4
for Chronic Pain Act of 2023’’. 5
SEC. 2. NATIONAL CHRONIC PAIN INFORMATION SYSTEM. 6
Part P of title III of the Public Health Service Act 7
(42 U.S.C. 280g et seq.) is amended by adding at the end 8
the following: 9
VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
•S 2922 IS
‘‘SEC. 399V–8. CHRONIC PAIN RESEARCH. 1
‘‘(a) I
NGENERAL.—The Secretary, acting through 2
the Director of the Centers for Disease Control and Pre-3
vention in consultation with the Director of the National 4
Center for Injury Prevention and Control and the Director 5
of the National Center for Chronic Disease Prevention and 6
Health Promotion, and in coordination with the NIH 7
Helping to End Addiction Long-term Initiative and with 8
other agencies as the Secretary determines appropriate, 9
shall— 10
‘‘(1) utilize available Federal research data to 11
clarify the incidence and prevalence of chronic pain 12
from any source, including injuries, operations, and 13
diseases and conditions; 14
‘‘(2) identify gaps in the available research data 15
and collect deidentified population research data 16
using medical claims and survey data to fill gaps in 17
available research data, such as information con-18
cerning— 19
‘‘(A) incidence and prevalence of specific 20
pain conditions; 21
‘‘(B) demographics and other information, 22
such as age, race, ethnicity, gender, and geo-23
graphic location; 24
‘‘(C) the incidence and prevalence of 25
known chronic pain conditions, as well as of 26
VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
kjohnson on DSK7ZCZBW3PROD with $$_JOB 3
•S 2922 IS
diseases and conditions that include or lead to 1
pain; 2
‘‘(D) risk factors that may be associated 3
with chronic pain conditions, such as genetic 4
and environmental risk factors and other infor-5
mation, as appropriate; 6
‘‘(E) diagnosis and progression markers; 7
‘‘(F) both direct and indirect costs of ill-8
ness; 9
‘‘(G) the epidemiology of the conditions; 10
‘‘(H) the detection, management, and 11
treatment of the conditions; 12
‘‘(I) the epidemiology, detection, manage-13
ment, and treatment of frequent secondary or 14
co-occurring conditions, such as depressive, anx-15
iety, and substance use disorders; 16
‘‘(J) the utilization of medical and social 17
services by patients with chronic pain condi-18
tions, including the direct health care costs of 19
pain treatment, both traditional and alternative, 20
and the indirect costs (such as missed work, 21
public and private disability, and reduction in 22
productivity); and 23
VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
kjohnson on DSK7ZCZBW3PROD with $$_JOB 4
•S 2922 IS
‘‘(K) the effectiveness of evidence-based 1
treatment approaches on chronic pain condi-2
tions; 3
‘‘(3) develop, in collaboration with individuals 4
and organizations with appropriate chronic pain ex-5
pertise, including patients or patient advocates, epi-6
demiologists, representatives of national voluntary 7
health associations, health information technology 8
experts, clinicians, and research scientists, standard 9
definitions and approaches for population research 10
on chronic pain to efficiently promote greater com-11
parability of data; and 12
‘‘(4) disseminate, pursuant to the public 13
webpage under subsection (b), and, as appropriate, 14
to the public and to other Federal departments and 15
agencies, any findings, developed population research 16
standards, and available Federal data sources re-17
lated to chronic pain. 18
‘‘(b) D
ISSEMINATION.—The Secretary, acting 19
through the Director of the Centers for Disease Control 20
and Prevention, shall establish a public webpage, to be 21
known as the Chronic Pain Information Hub, that— 22
‘‘(1) aggregates and summarizes available Fed-23
eral data sources, indicators, and peer-reviewed re-24
search related to chronic pain; 25
VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
kjohnson on DSK7ZCZBW3PROD with $$_JOB 5
•S 2922 IS
‘‘(2) includes an up-to-date summary of com-1
plete, underway, and planned data collection and 2
analysis related to chronic pain that is conducted 3
and supported by the Centers for Disease Control 4
and Prevention; and 5
‘‘(3) translates research findings into clinical 6
tools and resources, recommendations for closing re-7
search gaps, and recommendations for population re-8
search standards for researchers, with recommenda-9
tions updated annually to incorporate research find-10
ings from the prior year. 11
‘‘(c) C
ONFLICTS OFINTEREST.—If an individual or 12
organization that collaborates with the Secretary in car-13
rying out subsection (a) receives a payment or other trans-14
fer of value of a type described in section 15
1128G(a)(1)(A)(vi) of the Social Security Act from a man-16
ufacturer of a drug (including a biological product) or de-17
vice that would be required to be disclosed pursuant to 18
section 1128G(a)(1) of the Social Security Act, if the indi-19
vidual or organization were a covered recipient or if such 20
disclosure were required upon request of or by designation 21
on behalf of a covered recipient pursuant to such section, 22
the individual or organization shall disclose to the Sec-23
retary information regarding such payment or other trans-24
VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
kjohnson on DSK7ZCZBW3PROD with $$_JOB 6
•S 2922 IS
fer of value. The Secretary shall make such disclosures 1
publicly available. 2
‘‘(d) R
EPORT.—Not later than 2 years after the date 3
of the enactment of the Advancing Research for Chronic 4
Pain Act of 2023, the Secretary shall submit a report to 5
Congress concerning the implementation of this section. 6
Such report shall include information on— 7
‘‘(1) the development and maintenance of the 8
Chronic Pain Information Hub; 9
‘‘(2) the information made available through 10
the Chronic Pain Information Hub; 11
‘‘(3) the data gaps identified, and planned ef-12
forts to address such gaps; 13
‘‘(4) the process established for soliciting feed-14
back from collaborators; and 15
‘‘(5) feedback received from collaborators. 16
‘‘(e) D
EFINITION.—In this section, the term ‘chronic 17
pain’ means persistent or recurrent pain lasting longer 18
than 3 months. 19
‘‘(f) A
UTHORIZATION OF APPROPRIATIONS.—To 20
carry out this section, there is authorized to be appro-21
priated such sums as may be necessary for each of fiscal 22
years 2024 through 2028.’’. 23
Æ
VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6301 E:\BILLS\S2922.IS S2922
kjohnson on DSK7ZCZBW3PROD with $$_JOB